InspireMD (STU:II2) Beginning Cash Position: €7.73 Mil (As of Mar. 2026)


STU:II2 InspireMD Inc STU:II2
47 GF Score
Price €0.63
GF Value €1.49
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is InspireMD Beginning Cash Position?

InspireMD STU:II2 +2.46% 47 Beginning Cash Position is €7.73 Mil as of Mar. 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.49 (Possible Value Trap). The stock has 3 warning signs investors should review.

InspireMD's Beginning Cash Position for the quarter that ended in Mar. 2026 was €7.73 Mil.

InspireMD's quarterly Beginning Cash Position increased from Sep. 2025 (€9.80 Mil) to Dec. 2025 (€54.15 Mil) but then declined from Dec. 2025 (€54.15 Mil) to Mar. 2026 (€7.73 Mil).

InspireMD's annual Beginning Cash Position increased from Dec. 2023 (€4.25 Mil) to Dec. 2024 (€9.21 Mil) and increased from Dec. 2024 (€9.21 Mil) to Dec. 2025 (€16.15 Mil).

InspireMD Beginning Cash Position Related Terms

InspireMD Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for InspireMD's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InspireMD Beginning Cash Position Chart

InspireMD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.19 11.33 4.25 9.21 16.15

InspireMD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.50 10.74 9.80 54.15 7.73
STU:II2
47GF Score
InspireMD Inc STU:II2
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InspireMD Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €7.73 Mil mean?
InspireMD (STU:II2) has a Beginning Cash Position of €7.73 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on InspireMD and its competitors.
Is InspireMD's Beginning Cash Position too high?
InspireMD's current Beginning Cash Position is €7.73 Mil. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Beginning Cash Position compare to TELA and BDMD?
InspireMD's Beginning Cash Position of €7.73 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on InspireMD and its competitors. InspireMD's current Beginning Cash Position is €7.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.49, compared to a current price of €0.63 — trading 58.1% below its estimated fair value. The current Beginning Cash Position is €7.73 Mil. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For InspireMD (STU:II2), the current Beginning Cash Position is €7.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InspireMD (STU:II2) Overvalued in 2026?

Based on GuruFocus' analysis, InspireMD stock appears to be undervalued. The current stock price of €0.63 is trading 58.1% below its estimated GF Value™ of €1.49. GuruFocus considers InspireMD to be Possible Value Trap.

Key valuation signals for STU:II2:

  • Beginning Cash Position: €7.73 Mil
  • GF Value™: €1.49 vs. price of €0.63 (58.1% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InspireMD Business Description

Other Exchanges NSPR:USA
Address 6303 Waterford District Drive, Suite 215, Miami, FL, USA, 33126
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score

Get the complete analysis for STU:II2

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€1.49
GF Value